February 6, 2024 News by Marisa Wexler, MS Real-world data can be used to compare efficacy of MS treatments Real-world data collected from a registry can be used to reliably compare the effectiveness of different multiple sclerosis (MS) treatments, so long as appropriate methodologies are employed to account for the messiness ā what researchers call confounding bias ā of real-world data, according to a new study. While registries…
February 10, 2023 News by Mary Chapman New remote monitoring system to be tested in MS patients in rehab Datos Health, a remote care automation company, is collaborating with the Shirley Ryan AbilityLab, in Illinois, on a study that will gauge the effectiveness of remote therapy monitoring in patients with various conditions and disorders, including multiple sclerosis (MS). The Shirley Ryan AbilityLab, based in Chicago, provides…
September 9, 2022 News by Lindsey Shapiro, PhD Immunoadsorption Better Than 2nd Round of Steroids for MS Relapse A type of blood-cleansing process called immunoadsorption worked better than a second round of methylprednisolone for treating relapse in multiple sclerosis (MS) patients who failed to respond to a first, standard cycle of the corticosteroid, a study found. Among people with relapsing MS, immunoadsorption also was associated with…
August 30, 2022 News by Marta Figueiredo, PhD Long-term Ponvory Treatment Safe, Effective in RRMS, Trial Data Show Long-term treatment with Ponvory (ponesimod) safely and effectively reduces the rate of relapses, slows disability worsening, and prevents brain volume decline in adults with relapsing-remitting multiple sclerosis (RRMS). Thatās according to eight years of data from patients enrolled in a now-completed Phase 2 clinical trial (NCT01006265)Ā and its…
September 14, 2020 News by Joana Carvalho, PhD #MSVirtual2020 ā Low Rituximab Doses Are Safer, as Effective as Higher Ones Low doses of rituximab, an anti-inflammatory medication used off-label to treat multiple sclerosis (MS), are safer and as effective as higher doses at reducing the frequency of relapses and the number of MS lesions, a clinical study shows. The study findings were presented at MSVirtual2020 by Luciana…
April 13, 2020 News by Joana Carvalho, PhD Tysabri Shows Safety, Effectiveness in Real-world RRMS Use: 10-year TOP Data Tysabri (natalizumab) is safe and shows robust, real-world effectiveness at reducing the frequency of relapses in people Ā with relapsing-remitting multiple sclerosis (RRMS), 10 years of data from a large, observational study report. Findings were reported in āLong-term safety and effectiveness of natalizumab treatment…
August 30, 2018 News by Marta Figueiredo, PhD Tecfidera, Gilenya Equally Effective, But More MS Patients Stop Tecfidera, Real-World Study Shows TecfideraĀ (dimethyl fumarate) and GilenyaĀ (fingolimod) are equally effective in treating multiple sclerosis (MS),Ā but Tecfidera shows higher rates of discontinuation, according to a real-world study. The study, āDiscontinuation and comparative effectiveness of dimethyl fumarate and fingolimod in 2 centers,ā was published in the journal Neurology Clinical…
November 14, 2016 News by Joana Fernandes, PhD Effectiveness and Safety of DMDs Top Patient Concerns with These Therapies, Survey Says In general, patients with multiple sclerosis (MS) choose their disease-modifying drug (DMD) treatment based on considerations of effectiveness and potential sideĀ effects. But the weight they assign to these considerations can differ widely, making it important they are part of treatment decisions, especially regarding DMDs. TheseĀ findingsĀ are in the report,Ā āIdentification and…
July 5, 2016 News by Katie McCallum Latest Findings on RRMS Oral Therapy Tecfidera (Dimethyl Fumarate) Detailed in New Report Since its approval by the U.S. Food and Drug Administration (FDA) in 2013,Ā TecfideraĀ (dimethyl fumarate) has emerged as a first-line treatment for relapsing-remitting multiple sclerosis (RRMS), the most common form of multiple sclerosis (MS). While two separate clinical trials demonstrated Tecfidera’s ability to significantly reduce both the rate of relapse…